Barbara Leiting
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Peptidase Inhibition and Analysis, Neuropeptides and Animal Physiology, Diabetes Treatment and Management, Enzyme Structure and Function, Bacterial Genetics and Biotechnology
Most-Cited Works
- → Inhibition of Human Caspases by Peptide-based and Macromolecular Inhibitors(1998)985 cited
- → (2R)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes(2004)814 cited
- → Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes(2005)490 cited
- → High-Level Expression of Soluble Protein inEscherichia coliUsing a His6-Tag and Maltose-Binding-Protein Double-Affinity Fusion System(1997)245 cited
- → Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII(2003)181 cited
- → (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]- pyridin-6-ylphenyl)butanamide: A Selective α-Amino Amide Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes(2006)121 cited
- → Fluoroolefins as amide bond mimics in dipeptidyl peptidase IV inhibitors(2008)106 cited
- → Substituted piperazines as novel dipeptidyl peptidase IV inhibitors(2004)97 cited
- → Support of1H NMR assignments in proteins by biosynthetically directed fractional13C-labeling(1992)93 cited
- → Discovery of potent and selective β-homophenylalanine based dipeptidyl peptidase IV inhibitors(2004)76 cited